Lenti-D gene therapy: Interim Phase II/III data

Interim data from 17 patients with childhood CALD in the open-label Phase II/III Starbeam (ALD-102) trial showed that bluebird bio’s Lenti-D gene therapy led to ALD protein expression in leukocytes of...